# Pharmacological effects and mechanisms of curcumin in animal models of Parkinson’s disease: a systematic review and meta-analysis

**Authors:** Bowen Pang, Qiang Fu, Huihan He, Xiangyu Guo, Ge Yang

PMC · DOI: 10.3389/fphar.2026.1779921 · Frontiers in Pharmacology · 2026-03-09

## TL;DR

This study reviews how curcumin helps in animal models of Parkinson’s disease by improving motor function and reducing inflammation and oxidative stress.

## Contribution

The study systematically summarizes curcumin’s neuroprotective mechanisms in Parkinson’s disease using a meta-analysis of animal models.

## Key findings

- Curcumin improved motor function in Parkinson’s disease animal models through multiple behavioral tests.
- Curcumin reduced inflammatory markers like interleukin-6 and tumor necrosis factor-α.
- Curcumin enhanced antioxidant activity by increasing superoxide dismutase and glutathione levels.

## Abstract

Curcumin has been demonstrated to possess promising neuroprotective potential in Parkinson’s disease; however, its overall effects remain inconclusive, and its multiple mechanisms of action have not been systematically summarized.

This systematic review and meta-analysis aimed to evaluate the pharmacological effects of curcumin in animal models of Parkinson’s disease and to investigate its potential mechanisms involving antioxidant, anti-inflammatory, and neuroprotective effects, thereby providing a theoretical basis for its potential clinical application in Parkinson’s disease.

A comprehensive search of four databases (EMBASE, PubMed, Web of Science, and the Cochrane Library) up to August 2025 identified 31 eligible studies involving a total of 552 animals. Methodological quality was assessed using the SYRCLE risk of bias tool. Standardized mean differences (SMDs) were calculated to evaluate the effects of curcumin on motor function, neurochemistry, inflammation, and oxidative stress in animal models of Parkinson’s disease.

The results demonstrated that curcumin intervention improved motor function in animal models of Parkinson’s disease, as evidenced by increased locomotor distance in the open field test (SMD = 1.25) and elevated mean velocity (SMD = 1.42), prolonged latency to fall in the rotarod test (SMD = 2.49), shortened descent time in the pole test (SMD = −1.16), and reduced traversal time on the balance beam (SMD = −2.27). Curcumin exhibited neuroprotective effects through increasing the number of tyrosine hydroxylase-positive cells (SMD = 2.12), maintaining dopamine levels (SMD = 4.11), and elevating 3,4-dihydroxyphenylacetic acid concentrations (SMD = 3.15). Regarding anti-inflammatory effects, curcumin significantly reduced multiple inflammatory markers, including interleukin-6 (SMD = −4.73), interleukin-1β (SMD = −3.30), tumor necrosis factor-α (SMD = −3.19), and nitric oxide (SMD = −4.91). With respect to antioxidant activity, curcumin significantly reduced malondialdehyde levels (SMD = −4.69) while increasing the activities of superoxide dismutase (SMD = 3.90), glutathione (SMD = 2.08), and catalase (SMD = 2.00).

Curcumin demonstrates significant neuroprotective effects in Parkinson’s disease animal models, improving motor deficits and neuronal integrity likely through multi-target mechanisms involving anti-inflammatory and antioxidant pathways.

https://www.crd.york.ac.uk/PROSPERO/view/CRD420251131257, identifier CRD420251131257

## Linked entities

- **Chemicals:** curcumin (PubChem CID 969516), nitric oxide (PubChem CID 145068), malondialdehyde (PubChem CID 10964), glutathione (PubChem CID 124886), 3,4-dihydroxyphenylacetic acid (PubChem CID 547)
- **Diseases:** Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CAT (catalase) [NCBI Gene 847], TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, TH (tyrosine hydroxylase) [NCBI Gene 7054] {aka DYT14, DYT5b, TYH}
- **Diseases:** Parkinson's disease (MESH:D010300), motor deficits (MESH:D009461), inflammation (MESH:D007249)
- **Chemicals:** Curcumin (MESH:D003474), nitric oxide (MESH:D009569), malondialdehyde (MESH:D008315), 3,4-dihydroxyphenylacetic acid (MESH:D015102), dopamine (MESH:D004298), glutathione (MESH:D005978)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13006684/full.md

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13006684/full.md

## References

73 references — full list in the complete paper: https://tomesphere.com/paper/PMC13006684/full.md

---
Source: https://tomesphere.com/paper/PMC13006684